Short Communication

A New Physio-Anantomic Brain Map

Luisetto M¹* and Behzad Nili-Ahmadabadi²

¹Applied pharmacologist, European Specialist in Lab Medicine, Italy

²Independent researcher, USA

Submission: September 27, 2017;Published: November 22, 2017

*Corresponding author: Luisetto M, Applied Pharmacologist, European Specialist in Lab Medicine, Italy, Email: Maurolu65@gmail.com

How to cite this article: Luisetto M, Behzad N. A New Physio-Anantomic Brain Map. Theranostics Brain Spine Neuro Disord. 2017; 2(4): 555594. DOI: 10.19080/TBSND.2017.02.555594

Keywords

Brain maps; Neuroscience; Emotional systems

Introduction

We have see in last 2 centuries different way to have a brain map using various strategies. Since from BROADMAN theories we have see the introducing of technologies to support this working methods. (old and new) as EEG,TC, PET, FMRI, MEG, NIRS ant other with the scope to differentiates brain area in order to show their specific activity .

This has make possible to produce an anatomic image and map about the different brain area to be related with some different functions or dysfunctions. But what we can think is to create a new anatomic brain map using the drugs and substances that show high activity level in neurology field [1].

In example a new pharmacology brain map can be obtained using different molecules or physiopatological conditions:

A. BDZ GABA receptor, Barbiturate, Opioids, Neuroleptics, Antiepileptics, Andidepressive, Ipnotics

B. Anti migraine, Anfetaminic, Anti Parkinson, Antidementia, Antimuscarinics, Anticholinergics

C. Analgesics, Generalanaestetics, Antistaminics, Poisons and Toxins, Antipiretics, Antipertensives

D. Addiction substantives, Ethanol, Nicotine, New smart drugs, Heavy metals

E. Vegetals substances, Cannabinoids, Oxygen and Co2,Toxic substances (as cyanide ), insulin

F. Food (involved in Leptin methabolsims), carbohydrates level, metabolic toxic subst. MABS and many other drugs and substantives or physio-phatological conditions.

This map must be created adding the single signal in a complex design in order to achieve a different point of view in neurosciences. We can also see that some brain condition (as EMOTIONAL STATUS) are not covered today by drugs registered for this indication (by pharmaceutical industries) and this conditions need a deeply research about the real reason [2].

In our opinion can be relevant is to verify the function of some brain area and systems not covered by drugs other pharmacological substances effect. Why many area and brain systems are interested by pharmaceutical industry activity and other no? This approach can be useful in some field as forensic science, jurisdictional settings, HR management, and many other (Emotional Systems).

Discussion and Conclusion

Under the light of this consideration we submit to scientific community a new method to create and anatomical brain map to be associated to the existing methods [3].

Every subtantia or drugs (or condition) we have see interact with a specific area or system and we can easily Coniugate with radioactive or other molecular tracer to detect whit imaging the specific area involved. The same using other physic or neuro active molecule or physiologic –pathologic conditions. We can think to add this approach with the other existing today to have a more interesting brain phisio-anatomic schema.

Is not a new procedure but we think is innovative is to create a complexive map using this information. (What cells involved and related intensity of signal and objective able effect). Information that come from directly from the cell or systems involved. We can have a physiology and anatomic information complete related whit the efficacy of some drugs or substances [4].

This approach start from observing some brain disease (or systemic) and the effect due by some iatrogenic or toxic substanties and the drugs (used in therapy). To a pathology is related a system o neurons dysfunctions (or other noxa) and an efficacy drugs link to this or modulate them. Observing in a complexive way all this evidence we can have an global new image of brain physioanantomy.

We have written this paper observing that in some brain condition until today we don’t have registered drugs (in example in field of emotional system) and with the scope to give a more objective way in pharmacological molecule evaluation (effect objectively verified by instrumental or physical-bio chemistry methods).

Clarification

This Short Communication has not any diagnostic or therapeutic intent, only written in order to Produce research hypothesis.

References

1. Luisetto M, Farhan AK, Cabianca L, Mokbul MI, Yesvi Rafa A, et al. (2016) Amygdale pharmacology and crime behavior, dysfunctions to be considered as a disease? IABCR International Archives of Biomedical and Clinical Research 2(2): 1-4.
2. Luisetto M (2017) Brain and transmission signal modulation. Theranostics Brain Spine Neuro Disord 1(1): 1.
3. Luisetto M (2017) Attitudes and skills in business working settings: A HR management tool. Business and economics journal 8: 1.
4. Luisetto M (2017) The Economic costs of some preventable brain disorder. Theranostics Brain Spine Neuro Disord 1(4): 1.